Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
about
Meta-analysis on the effects of octreotide on tumor mass in acromegalyOptimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.Pituitary tumors. Current concepts in diagnosis and managementPrimary medical therapy for acromegaly.Medical therapy of acromegalyCentral and peripheral actions of somatostatin on the growth hormone-IGF-I axis.From somatostatin to octreotide LAR: evolution of a somatostatin analogueMedical therapy in acromegaly.Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue.Advances in medical therapy for pituitary disease: treating patients with growth hormone excess and deficiency.Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.Treatment Options in Gastrointestinal Cutaneous Fistulas.
P2860
Q28730120-82CC6667-5BD5-426F-86F1-D325C695ADC6Q33422743-10848B8A-008E-4D65-B1B1-F406F442D573Q33608512-A20A303C-9EAE-4F26-973B-D71F2C7F5909Q35086868-880B0AB4-9E58-471A-997D-92A0138862D8Q35895856-6016E1BF-0A6F-4879-B55B-9ACCE35989F8Q36849036-F940305F-75D9-4BC5-83DB-E1F145C3F447Q36919554-AEC037B8-811B-469F-8D06-BDF154512BC0Q37859250-436CF1C6-14A5-41B5-B878-DEB30B84E17CQ38555292-D6DBD297-02B3-4932-A801-856C09C38374Q40711627-805C41A0-5F5A-4BDA-9439-660729F9AF30Q42482027-BC8CA572-4199-413F-9D14-55B2DAB99FFBQ42486526-E8BA5C85-27E2-4DA8-92C5-DAB613452654Q43201636-E1BD5900-0A5D-407E-9D19-1C9D8CE486E3Q43952010-8D214578-242A-4E58-9AA2-FE30F34F06FBQ44331741-838261AA-5B86-44F1-84CE-AE6102A8CE92Q44910768-5FA4D314-3E0C-49C0-81DE-BE3A369773CAQ44992381-A377DD3A-8215-4330-A33B-298D3EA69146Q46951312-7CA447F0-5316-4B4E-A967-AB2B700EC504Q48474600-F31632C1-5530-4722-8EC7-4FB63FDF452CQ51561907-E56098A8-E275-4657-93A2-3441FDA461F7Q53925916-B006D4D7-83C2-42E7-A09E-A4EEFB429B89Q55021317-3B306E8F-4D3A-4E5C-8B7F-C9CF0C70B1B5
P2860
Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@ast
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@en
type
label
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@ast
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@en
prefLabel
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@ast
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@en
P1476
Long-term treatment of 189 acr ...... center Acromegaly Study Group.
@en
P2093
P304
P356
10.1001/ARCHINTE.151.8.1573
P407
P577
1991-08-01T00:00:00Z